Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression

In Situ Estrogen Production via the Estrone Sulfatase Pathway in Breast Tumors: Relative Importance versus the Aromatase Pathway*

Steven J. Santner, Peter D. Feil, Richard J. Santen · The Journal of Clinical Endocrinology & Metabolism · 1984 · 406 citations

Life Sciences, Biochemistry, Oncology +17

Aminoglutethimide Inhibits Extraglandular Estrogen Production in Postmenopausal Women with Breast Carcinoma*

Richard J. Santen, Steven J. Santner, BONNIE DAVIS et al. · The Journal of Clinical Endocrinology & Metabolism · 1978 · 341 citations

Life Sciences, Endocrinology, Pharmacology +17

Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.

Mitch Dowsett, Paul E. Goss, TJ Powles et al. · PubMed · 1987 · 240 citations

Medicine, Oncology, Pharmacology +17

Aminoglutethimide as Treatment of Postmenopausal Women with Advanced Breast Carcinoma

Richard J. Santen, Thomas J. Worgul, Allan Lipton et al. · Annals of Internal Medicine · 1982 · 171 citations

Medicine, Endocrinology, Oncology +17

Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.

T.R. Jeffry Evans, E. Di Salle, G. Ornati et al. · PubMed · 1992 · 150 citations

Medicine, Endocrinology, Pharmacology +17